<DOC>
	<DOCNO>NCT00257114</DOCNO>
	<brief_summary>Multiple myeloma represent second common hematological malignancy.VELCADE small molecule treat human malignancy . Its anti-neoplastic effect invovles several distinct mechanism include inhibition cell growth . Patients relapse refractory therapy , standard care VELCADE base result previous clinical trial .</brief_summary>
	<brief_title>Evaluation VELCADE Given Retreatment Multiple Myeloma Patients Efficacy , Safety Tolerability</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Voluntary write informed consent understand consent may w/d patient time w/o prejudice future medical care . 2 . Patient previously diagnose Multiple Myeloma ( MM ) . 3 . Patient previously tolerate 0.7 , 1.0 , 1.3 mg/m2/dose VELCADE alone therapy combination least greater/equal 50 % reduction MProtein upon completion VELCADE therapy . The DOR prior VELCADE greater/equal 4 month patient population . 4 . It greater/equal 2 month since patient 's last VELCADE dose patient meet certain Lab criterion per protocol . 5 . Patient Karnosfsky performance status greater/equal 60 % . 6 . Patient lifeexpectancy great 3 month . 7 . Patient laboratory value ( define protocol ) within 14 day enrollment . 1 . Patients Hx PD , minimal response , stable disease ( SD ) first exposure VELCADE . 2 . Patient receive chemotherapy , radiotherapy , immunotherapy experimental therapy treat multiple myeloma since last dose VELCADE . 3 . Patients achieve CR PR relapse therapy . 4 . Patient major surgery w/in 2 wks enrollment . 5 . Patient Hx allergic reaction compound contain boron mannitol . 6 . Patient peripheral sensory neuropathy Grade 2 w/pain great intensity . 7 . Patient cardiac amyloidosis . 8 . Patient poorly control hypertension , diabetes mellitus , serious medical pysychiatric illness . 9 . Patient known human immunodeficiency virus ( HIV ) + . 10 . Patient know hepatitis B surface antigenpositive know active hepatitis C infection . 11 . Patient active systemic infection require treatment . 12 . Female patient pregnant breastfeeding . Confirmation must establish negative serum BhCG . 13 . Patient currently enrol another clinical research study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Retreatment</keyword>
	<keyword>VELCADE</keyword>
</DOC>